Odense University Hospital

• A Phase III trial (DIVERSITY) of filgotinib in Crohn's disease showed mixed results, failing to meet several primary endpoints for clinical remission and endoscopic response in induction studies. • In biologic-experienced patients, filgotinib 200mg achieved statistically significant clinical remission at week 10 compared to placebo (30% vs 18%, P=0.0039), but not in biologic-naive patients. • During the maintenance phase at 58 weeks, filgotinib 200mg demonstrated significant clinical and endoscopic remission compared to placebo (44% vs 26%, P=0.038 and 30% vs 9%, P=0.0038, respectively). • Experts suggest study design limitations, such as early endoscopic assessment and high corticosteroid use, may have masked filgotinib's efficacy, warranting further investigation.

Odense University Hospital

Filgotinib Fails to Meet Key Endpoints in Phase III Crohn's Disease Trial